Semaglutide vs Tirzepatide: the receptor-pathway difference, plainly

Educational pathway discussion, no human-use angle. The headline distinction in the literature: semaglutide is a GLP-1 receptor agonist; tirzepatide engages both GLP-1 and GIP receptors (a dual agonist). Retatrutide goes further as a triple agonist.

What I find under-explained for newcomers is why "more receptors" is an active research question rather than an automatic "better." Anyone have a good review paper that lays out the incretin pathways without assuming a pharmacology degree? Let's build a reading list.

Clear summary. The "more receptors ≠ automatically better" point is the right one to stress — the dual- and triple-agonist work is an open research question, not a settled ranking. For a non-specialist start, look for incretin-pathway review articles rather than primary trial papers.

Adding to the reading list: the GIP side is genuinely under-appreciated in casual write-ups. People hear "GLP-1 plus something" and skip what GIP signalling actually contributes. A good GIP review pairs well with this.

This is the cleanest plain-English version of the distinction I've seen. The receptor-engagement framing (single / dual / triple) is going straight into my notes.

Love that the thread stayed firmly on mechanism. Compiling the cited reviews into the top post so newcomers get the pathway map without the noise.

New here and this is the cleanest single/dual/triple-agonist explanation I've read. Saved the cited reviews. The "more receptors isn't automatically better" point is the bit most write-ups skip.

Want to join the discussion?

Semaglutide vs Tirzepatide: the receptor-pathway difference, plainly

Related reading

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide